11. Calkins BM, Lilienfeld AM, Garland CF, et al. Trends in incidence rates of ulcerative colitis and

Crohn’s disease. Dig Dis Sci 1984;29:913–920.

12. Mayberry JF, Judd D, Smart H, et al. Crohn’s disease in Jewish people–an epidemiological study in

south-east Wales. Digestion 1986;35:237–240.

13. Orholm M, Binder V, Sorensen TI, et al. Concordance of inflammatory bowel disease among Danish

twins. Results of a nationwide study. Scand J Gastroenterol 2000;35:1075–1081.

14. Halfvarson J, Bodin L, Tysk C, et al. Inflammatory bowel disease in a Swedish twin cohort: a longterm follow-up of concordance and clinical characteristics. Gastroenterology 2003;124:1767–1773.

15. Watts DA, Satsangi J. The genetic jigsaw of inflammatory bowel disease. Gut 2002;50(suppl

3):III31–36.

16. Laharie D, Debeugny S, Peeters M, et al. Inflammatory bowel disease in spouses and their

offspring. Gastroenterology 2001;120:816–839.

17. Cuthbert AP, Fisher SA, Mirza MM, et al. The contribution of NOD2 gene mutations to the risk and

1720

site of disease in inflammatory bowel disease. Gastroenterology 2002;122:867–874.

18. Fisher SA, Tremelling M, Anderson CA, et al. Genetic determinants of ulcerative colitis include the

ECM1 locus and five loci implicated in Crohn’s disease. Nat Genet 2008;40:710–712.

19. Franke A, Balschun T, Sina C, et al. Genome-wide association study for ulcerative colitis identifies

risk loci at 7q22 and 22q13 (IL17REL). Nat Genet 2010;42:292–294.

20. Rioux JD, Silverberg MS, Daly MJ, et al. Genomewide search in Canadian families with

inflammatory bowel disease reveals two novel susceptibility loci. Am J Hum Genet 2000;66:1863–

1870.

21. Glocker EO, Kotlarz D, Boztug K, et al. Inflammatory bowel disease and mutations affecting the

interleukin-10 receptor. N Engl J Med 2009;361:2033–2045.

22. Toyoda H, Wang SJ, Yang HY, et al. Distinct associations of HLA class II genes with inflammatory

bowel disease. Gastroenterology 1993;104:741–748.

23. Okada Y, Yamazaki K, Umeno J, et al. HLA-Cw*1202-B*5201-DRB1*1502 haplotype increases risk

for ulcerative colitis but reduces risk for Crohn’s disease. Gastroenterology 2011;141:864–871.e1–5.

24. Duerr RH, Taylor KD, Brant SR, et al. A genome-wide association study identifies IL23R as an

inflammatory bowel disease gene. Science 2006;314:1461–1463.

25. Silverberg MS, Cho JH, Rioux JD, et al. Ulcerative colitis-risk loci on chromosomes 1p36 and 12q15

found by genome-wide association study. Nat Genet 2009;41:216–220.

26. Loftus CG, Loftus EV Jr, Harmsen WS, et al. Update on the incidence and prevalence of Crohn’s

disease and ulcerative colitis in Olmsted County, Minnesota, 1940–2000. Inflamm Bowel Dis

2007;13:254–261.

27. Ekbom A, Helmick C, Zack M, et al. The epidemiology of inflammatory bowel disease: a large,

population-based study in Sweden. Gastroenterology 1991;100:350–358.

28. Loftus EV Jr, Silverstein MD, Sandborn WJ, et al. Ulcerative colitis in Olmsted County, Minnesota,

1940–1993: incidence, prevalence, and survival. Gut 2000;46:336–343.

29. Geerling BJ, Dagnelie PC, Badart-Smook A, et al. Diet as a risk factor for the development of

ulcerative colitis. Am J Gastroenterol 2000;95:1008–1013.

30. Jowett SL, Seal CJ, Pearce MS, et al. Influence of dietary factors on the clinical course of ulcerative

colitis: a prospective cohort study. Gut 2004;53:1479–1484.

31. Khalili H, Ananthakrishnan AN, Konijeti GG, et al. Physical activity and risk of inflammatory bowel

disease: prospective study from the Nurses’ Health Study cohorts. BMJ 2013;347:f6633.

32. Boyko EJ, Koepsell TD, Perera DR, et al. Risk of ulcerative colitis among former and current

cigarette smokers. N Engl J Med 1987;316:707–710.

33. Mahid SS, Minor KS, Soto RE, et al. Smoking and inflammatory bowel disease: a meta-analysis.

Mayo Clin Proc 2006;81:1462–1471.

34. Calkins BM. A meta-analysis of the role of smoking in inflammatory bowel disease. Dig Dis Sci

1989;34:1841–1854.

35. Loftus EV Jr, Sandborn WJ, Tremaine WJ, et al. Primary sclerosing cholangitis is associated with

nonsmoking: a case-control study. Gastroenterology 1996;110:1496–1502.

36. van Erpecum KJ, Smits SJ, van de Meeberg PC, et al. Risk of primary sclerosing cholangitis is

associated with nonsmoking behavior. Gastroenterology 1996;110:1503–1506.

37. Frisch M, Biggar RJ: Appendectomy and protection against ulcerative colitis. N Engl J Med

2001;345:222–223; author reply 223–224.

38. Frisch M, Johansen C, Mellemkjaer L, et al. Appendectomy and subsequent risk of inflammatory

bowel diseases. Surgery 2001;130:36–43.

39. Andersson RE, Olaison G, Tysk C, et al. Appendectomy and protection against ulcerative colitis. N

Engl J Med 2001;344:808–814.

40. Rutgeerts P, D’Haens G, Hiele M, et al. Appendectomy protects against ulcerative colitis.

Gastroenterology 1994;106:1251–1253.

41. Sandler RS. Appendicectomy and ulcerative colitis. Lancet 1998;352:1797–1798.

42. Holtmann MH, Galle PR. Current concept of pathophysiological understanding and natural course

of ulcerative colitis. Langenbecks Arch Surg 2004;389:341–349.

43. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological

1721

classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal

World Congress of Gastroenterology. Can J Gastroenterol 2005;19(suppl A):5A–36A.

44. Sands BE. From symptom to diagnosis: clinical distinctions among various forms of intestinal

inflammation. Gastroenterology 2004;126:1518–1532.

45. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to

moderately active ulcerative colitis. a randomized study. N Engl J Med 1987;317:1625–1629.

46. Shetty K, Rybicki L, Brzezinski A, et al. The risk for cancer or dysplasia in ulcerative colitis patients

with primary sclerosing cholangitis. Am J Gastroenterol 1999;94:1643–1649.

47. Suhler EB, Smith JR, Wertheim MS, et al. A prospective trial of infliximab therapy for refractory

uveitis: preliminary safety and efficacy outcomes. Arch Ophthalmol 2005;123:903–912.

48. Farhi D, Cosnes J, Zizi N, et al. Significance of erythema nodosum and pyoderma gangrenosum in

inflammatory bowel diseases: a cohort study of 2402 patients. Med (Baltimore) 2008;87:281–293.

49. Agarwal A, Andrews JM. Systematic review: IBD-associated pyoderma gangrenosum in the biologic

era, the response to therapy. Aliment Pharmacol Ther 2013;38:563–572.

50. Generini S, Giacomelli R, Fedi R, et al. Infliximab in spondyloarthropathy associated with Crohn’s

disease: an open study on the efficacy of inducing and maintaining remission of musculoskeletal

and gut manifestations. Ann Rheum Dis 2004;63:1664–1669.

51. Gee MS, Harisinghani MG. MRI in patients with inflammatory bowel disease. J Magn Reson Imaging

2011;33:527–534.

52. Geboes K, De Hertogh G. Indeterminate colitis. Inflamm Bowel Dis 2003;9:324–331.

53. Faubion WA Jr, Loftus EV Jr, Harmsen WS, et al. The natural history of corticosteroid therapy for

inflammatory bowel disease: a population-based study. Gastroenterology 2001;121:255–260.

54. Rutgeerts P, Lofberg R, Malchow H, et al. A comparison of budesonide with prednisolone for active

Crohn’s disease. N Engl J Med 1994;331:842–845.

55. Travis SP: Predicting outcome in severe ulcerative colitis. Dig Liver Dis 2004;36:448–449.

56. Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with

therapies for Crohn’s disease: TREAT registry. Clin Gastroenterol Hepatol 2006;4:621–630.

57. d’Albasio G, Pacini F, Camarri E, et al. Combined therapy with 5-aminosalicylic acid tablets and

enemas for maintaining remission in ulcerative colitis: a randomized double-blind study. Am J

Gastroenterol 1997;92:1143–1147.

58. Higgins PD, Rubin DT, Kaulback K, et al. Systematic review: impact of non-adherence to 5-

aminosalicylic acid products on the frequency and cost of ulcerative colitis flares. Aliment Pharmacol

Ther 2009;29:247–257.

59. Kane S, Huo D, Aikens J, et al. Medication nonadherence and the outcomes of patients with

quiescent ulcerative colitis. Am J Med 2003;114:39–43.

60. Lichtiger S. Cyclosporine therapy in inflammatory bowel disease: open-label experience. Mt Sinai J

Med 1990;57:315–319.

61. Rayner CK, McCormack G, Emmanuel AV, et al. Long-term results of low-dose intravenous

ciclosporin for acute severe ulcerative colitis. Aliment Pharmacol Ther 2003;18:303–308.

62. D’Haens G, Baert F, van Assche G, et al. Early combined immunosuppression or conventional

management in patients with newly diagnosed Crohn’s disease: an open randomised trial. Lancet

2008;371:660–667.

63. Mason M, Siegel CA. Do inflammatory bowel disease therapies cause cancer? Inflamm Bowel Dis

2013;19:1306–1321.

64. George J, Present DH, Pou R, et al. The long-term outcome of ulcerative colitis treated with 6-

mercaptopurine. Am J Gastroenterol 1996;91:1711–1714.

65. Laharie D, Seneschal J, Schaeverbeke T, et al. Assessment of liver fibrosis with transient

elastography and FibroTest in patients treated with methotrexate for chronic inflammatory

diseases: a case-control study. J Hepatol 2010;53:1035–1040.

66. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for

ulcerative colitis. N Engl J Med 2005;353:2462–2476.

67. Reinisch W, Sandborn WJ, Rutgeerts P, et al. Long-term infliximab maintenance therapy for

ulcerative colitis: the ACT-1 and -2 extension studies. Inflamm Bowel Dis 2012;18:201–211.

1722

68. Sokol H, Seksik P, Carrat F, et al. Usefulness of co-treatment with immunomodulators in patients

with inflammatory bowel disease treated with scheduled infliximab maintenance therapy. Gut

2010;59:1363–1368.

69. Ford AC, Sandborn WJ, Khan KJ, et al. Efficacy of biological therapies in inflammatory bowel

disease: systematic review and meta-analysis. Am J Gastroenterol 2011;106:644–659, quiz 660.

70. Crum NF, Lederman ER, Wallace MR. Infections associated with tumor necrosis factor-alpha

antagonists. Med (Baltimore) 2005;84:291–302.

71. Wallis RS, Broder MS, Wong JY, et al. Granulomatous infectious diseases associated with tumor

necrosis factor antagonists. Clin Infect Dis 2004;38:1261–1265.

72. Mariette X, Tubach F, Bagheri H, et al. Lymphoma in patients treated with anti-TNF: results of the

3-year prospective French RATIO registry. Ann Rheum Dis 2010;69:400–408.

73. Langholz E, Munkholm P, Davidsen M, et al. Colorectal cancer risk and mortality in patients with

ulcerative colitis. Gastroenterology 1992;103:1444–1451.

74. Allison J, Herrinton LJ, Liu L, et al. Natural history of severe ulcerative colitis in a communitybased health plan. Clin Gastroenterol Hepatol 2008;6:999–1003.

75. Grant CS, Dozois RR. Toxic megacolon: ultimate fate of patients after successful medical

management. Am J Surg 1984;147:106–110.

76. Jarnerot G, Hertervig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately

severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 2005;128:1805–

1811.

77. Albrechtsen D, Bergan A, Nygaard K, et al. Urgent surgery for ulcerative colitis: early colectomy in

132 patients. World J Surg 1981;5:607–615.

78. Hawley PR. Emergency surgery for ulcerative colitis. World J Surg 1988; 12:169–173.

79. Robert JH, Sachar DB, Aufses AH Jr, et al. Management of severe hemorrhage in ulcerative colitis.

Am J Surg 1990;159:550–555.

80. van Heerden JA, Beart RW Jr. Carcinoma of the colon and rectum complicating chronic ulcerative

colitis. Dis Colon Rectum 1980;23:155–159.

81. Lavery IC, Chiulli RA, Jagelman DG, et al. Survival with carcinoma arising in mucosal ulcerative

colitis. Ann Surg 1982;195:508–512.

82. Rutter MD, Saunders BP, Wilkinson KH, et al. Thirty-year analysis of a colonoscopic surveillance

program for neoplasia in ulcerative colitis. Gastroenterology 2006;130:1030–1038.

83. Itzkowitz SH, Present DH, Crohn’s and Colitis Foundation of America Colon Cancer in IBD Study

Group. Consensus conference: colorectal cancer screening and surveillance in inflammatory bowel

disease. Inflamm Bowel Dis 2005;11:314–321.

84. Murphy J, Kalkbrenner KA, Pemberton JH, et al. Dysplasia in ulcerative colitis as a predictor of

unsuspected synchronous colorectal cancer. Dis Colon Rectum 2014;57:993–998.

85. Goudet P, Dozois RR, Kelly KA, et al. Characteristics and evolution of extraintestinal manifestations

associated with ulcerative colitis after proctocolectomy. Dig Surg 2001;18:51–55.

86. Holubar SD, Larson DW, Dozois EJ, et al. Minimally invasive subtotal colectomy and ileal pouchanal anastomosis for fulminant ulcerative colitis: a reasonable approach? Dis Colon Rectum

2009;52:187–192.

87. Holubar SD, Privitera A, Cima RR, et al. Minimally invasive total proctocolectomy with Brooke

ileostomy for ulcerative colitis. Inflamm Bowel Dis 2009;15:1337–1342.

88. Boller AM, Larson DW. Laparoscopic restorative proctocolectomy for ulcerative colitis. J

Gastrointest Surg 2007;11:3–7.

89. Rosenstein DI, Alsikafi NF. Diagnosis and classification of urethral injuries. Urol Clin North Am

2006;33:73–85, vi-vii.

90. MacLean AR, Cohen Z, MacRae HM, et al. Risk of small bowel obstruction after the ileal pouch–

anal anastomosis. Ann Surg 2002;235:200–206.

91. Scott NA, Dozois RR, Beart RW Jr, et al. Postoperative intra-abdominal and pelvic sepsis

complicating ileal pouch–anal anastomosis. Int J Colorectal Dis 1988;3:149–152.

92. Heuschen UA, Allemeyer EH, Hinz U, et al. Outcome after septic complications in J-pouch

procedures. Br J Surg 2002;89:194–200.

1723